Effect of amyloid, tau and syndromic stages of Alzheimer's disease (AD) in speech markers: A potential scalable tool for screening in AD clinical trials
Our results suggest that subtle tau driven changes in speech fluency begin as early as preclinical stage highlighting the potential utilization of speech markers in improving screening in AD clinical trials. This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (grant No 806999). www.imi.europa.eu. This communication reflects the views of the RADAR-AD consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
Authors
- Cornelia M. van Duijn (ORCID: https://orcid.org/0000-0002-2374-9204)
- Srinivasan Vairavan (ORCID: https://orcid.org/0000-0001-7975-8436)
- C.N. Hinds
- Claire Lancaster (ORCID: https://orcid.org/0000-0001-5169-1575)
- Neva Coello (ORCID: https://orcid.org/0000-0003-0791-7543)
- Gayle Wittenberg (ORCID: https://orcid.org/0009-0004-4299-5138)
- Alankar Atreya
- Sarah Parish (ORCID: https://orcid.org/0000-0003-3532-0832)
- Jelena Curcic (ORCID: https://orcid.org/0000-0001-9647-5972)
- Marion Mafham (ORCID: https://orcid.org/0000-0003-0562-3963)
- Anna‐Katharine Brem
- Nicholas Cummins (ORCID: https://orcid.org/0000-0002-1178-917X)
- Dag Aarsland
Institutions
- Novartis (Switzerland) (CH)
- Johnson & Johnson (United States) (US)
- King's College London (GB)
- Trinity College London (GB)
- University of Oxford (GB)
- Janssen (United States) (US)
- Novartis Institutes for BioMedical Research
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70856_102581
- Primary Topic
- Neurobiology of Language and Bilingualism
- Type
- article
- Field-Weighted Citation Impact
- 0.00